Drug intelligence / Profile preview

SER-214

Development stage: Preclinical
Lead developer: Serentrix
Modality: Small Molecules
Administration: Subcutaneous

Overview

SER-214 is a small molecule antagonist of the Transient Receptor Potential Vanilloid 1 (TRPV1) receptor, currently in preclinical development by Serentrix for the treatment of Irritable Bowel Diseases (IBD). TRPV1 is a non-selective cation channel involved in the transmission of pain and inflammatory signals. Unlike earlier generations of TRPV1 antagonists that were associated with adverse hyperthermic effects, SER-214 is specifically designed to block TRPV1 activity while maintaining normal body temperature regulation.

Targets

DRD (Dopamine receptors)

Beyond the preview

Go deeper on SER-214.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SER-214.

Explore the full profile